undamentalytics Newsletter
Sign in

Editas Medicine, Inc. (EDIT) stock

Add to watchlist

Add holding +

NASDAQ: EDIT Nasdaq Biotechnology Next results ~November 9, 2026

C+ Fundamentals grade

Editas Medicine, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.1

Valuation models combined (2)

Base case. Range ~$0.6–$1.2. Weighted average of 2 models (growth cash-flow model, forward price-to-sales vs peers), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Editas Medicine, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 14 sales by directors and officers, last 12 monthsInsider trades
  • Funds110 adding, 65 cuttingOf 34 active managers that changed their stake, 23 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Editas Medicine files

Where Editas Medicine stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $47m, up 20.8% on a year earlier, faster than the 8.0% growth a quarter earlier. Free-cash-flow margin rose to -256.5% from -526.8% a year earlier. Operating margin widened to -161.4% from -616.9%. The diluted share count is up 21.7% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 3 of our 6 financial-health checks. Our price-to-sales vs peers value is $1.00 a share, against a share price of $2.96.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Editas Medicine, Inc.'s trailing-twelve-month revenue grew 20.8% year on year, with a free-cash-flow margin of -256.5%.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 41.2% while net income grew 68.8%: a 28pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 20.8% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 12.9 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 455.5 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -161.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -256.5% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 18.4% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 21.7% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 82% and a beta of 2.4 against the S&P 500.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.15 against an average estimate of -$0.28: beat by 46.2%
Revenue
$12m, up 232.3% on a year earlier
Share reaction
+4.7% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Next report
November 9, 2026; average EPS estimate -$0.21

Editas Medicine's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.7%
  • 1 week+7.1%
  • 1 month-1.9%
  • This year+25.4%
  • 1 year-16.6%
  • 5 years-93.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$47M
Operating margin
-161.4%
Net margin
-157.3%
EPS (TTM, diluted)
$-0.73

Growth

Revenue growth
+20.8%
Change in growth rate
+12.9 pts
Share count change
+21.7%

Cash

Free cash flow (TTM)
-$121M
FCF margin
-256.5%
Stock pay % of revenue
18.4%

Earnings

Last results
August 5, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Editas Medicine, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Editas Medicine, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.39 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.2 ~$1.1–$1.2 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.6 ~$0.6–$2.3 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.1 ~$0.6–$1.2 2 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Editas Medicine, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$16.23$30.73$22.75$29.61$70.11$26.55$8.87$10.13$1.27$2.05$2.57
Market value$523m$1.2bn$1.1bn$1.5bn$4.1bn$1.8bn$609m$770m$105m$182m$260m
+ Net debt (− = net cash)−$185m−$147m−$135m−$238m−$140m−$204m−$142m−$124m−$74m−$88m−$126m
Enterprise value$338m$1.1bn$937m$1.2bn$4.0bn$1.6bn$468m$646m$30m$94m$134m
Multiples
Price / sales 86.4x90.3x33.5x72.1x45.3x70.3x30.9x9.9x3.2x4.5x5.5x
Price / earnings ———————————
Price / free cash flow ———————————
EV / EBITDA ———————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

8 /100

Weak moat

How hard Editas Medicine's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -31.9% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -466.1%; its worst year was -1118.4%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 9 years, at a median -263.2% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 56.6% over five years; stock-based pay has been a median 75.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 9, 2026, after the close. Analysts expect revenue of $5m and EPS of −$0.21 (range −$0.25 to −$0.19) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.83 +54% $26m −36%
Next −$0.75 +9% $19m −25%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −16.2% on 90 days ago. In the last 30 days, 5 analysts raised Editas Medicine, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Editas Medicine, Inc., last 90 days
−$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.99 Current fiscal year, 60 days ago: −$1.00 Current fiscal year, 30 days ago: −$1.00 Current fiscal year, 7 days ago: −$0.99 Current fiscal year, Now: −$0.83 −$0.83 Next fiscal year, 90 days ago: −$0.91 Next fiscal year, 60 days ago: −$0.94 Next fiscal year, 30 days ago: −$0.94 Next fiscal year, 7 days ago: −$0.96 Next fiscal year, Now: −$0.75 −$0.75

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.99−$0.91
60 days ago −$1.00−$0.94
30 days ago −$1.00−$0.94
7 days ago −$0.99−$0.96
Now −$0.83−$0.75

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.28 −$0.15 +46.2%
Mar 2026 −$0.24 −$0.26 −7.6%
Dec 2025 −$0.21 −$0.06 +72.1%
Sept 2025 −$0.38 −$0.28 +27.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026

No numeric guidance in Editas Medicine, Inc.'s latest earnings release (filed August 5, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

13 analysts, Oct 2026
Buy969%
Hold215%
Sell215%

Monthly trend

  1. Oct 202692213
  2. Sep 202683213
  3. Aug 202674213
  4. Jul 202664212

Counts of recommendations published by analysts covering Editas Medicine, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
24.9%
of tradable shares
Days to cover
11.66
at average volume
Short interest, 1 month
+27%
to October 15, 2026
Held by institutions
79%
of shares
Held by insiders
0.2%
of shares
Employees
87
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −16.6%

$3.08 on October 31, 2025 to $2.57

ThenNowEffect
Revenue (last 12 months) $39m $47m +20.8%
P/S multiple 6.6x 5.5x −16.0%
Share count 83m 101m −17.8%

Biggest factor: share count. Loss-making at one end, so the split uses price/sales.

Last 3 years −69.1%

$8.31 on November 3, 2023 to $2.57

ThenNowEffect
Revenue (last 12 months) $19m $47m +143.3%
P/S multiple 29.9x 5.5x −81.5%
Share count 69m 101m −31.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
EDIT−62%−67%+14%−88%+61%+25%
Industry peers (median)−35%−56%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
EDIT17%33%50%17%67%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
EDIT−71%−70%−46%−89%−69%−40%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since February 3, 2016: 99% from January 8, 2021 to April 8, 2025. Getting back needed a 9143% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.67 – $3.75
From 52-week high
−31.5%
vs 50-day average
−6.5%
vs 200-day average
−4.2%
Volatility (1 year)
82%
Beta vs S&P 500
2.40

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±11.5%
After a week
7 up, 5 down
typical move ±11.1%
After a month
5 up, 7 down
typical move ±21.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 +4.7% −0.4% +2.5% +11.2%
May 5, 2026 +5.8% +2.2% −2.3% −0.3%
March 9, 2026 +32.0% +0.7% +27.0% +38.0%
November 10, 2025 +7.7% +1.8% +4.5% +5.3%
August 12, 2025 +40.0% +1.4% +19.5% +23.2%
May 12, 2025 +3.4% +4.0% +2.8% +40.0%
March 5, 2025 +1.1% −0.7% −14.2% −36.4%
January 13, 2025 −9.5% +0.3% −4.0% −5.6%
November 4, 2024 +7.2% +1.0% +13.4% −31.6%
October 22, 2024 −14.6% −1.0% −17.3% −35.9%
August 7, 2024 −10.1% +1.6% −20.1% −23.3%
May 8, 2024 −2.1% +0.6% +5.6% −6.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Editas Medicine, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Editas Medicine, Inc.
$0 $20M $40M $60M $80M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $24.6M Revenue (TTM), FY23 Q4: $78.1M Revenue (TTM), FY24 Q1: $69.4M Revenue (TTM), FY24 Q2: $67M Revenue (TTM), FY24 Q3: $61.8M Revenue (TTM), FY24 Q4: $32.3M Revenue (TTM), FY25 Q1: $35.8M Revenue (TTM), FY25 Q2: $38.9M Revenue (TTM), FY25 Q3: $46.4M Revenue (TTM), FY25 Q4: $40.5M Revenue (TTM), FY26 Q1: $38.7M Revenue (TTM), FY26 Q2: $47M $47M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $24.6M
FY23 Q4 $78.1M
FY24 Q1 $69.4M
FY24 Q2 $67M
FY24 Q3 $61.8M
FY24 Q4 $32.3M
FY25 Q1 $35.8M
FY25 Q2 $38.9M
FY25 Q3 $46.4M
FY25 Q4 $40.5M
FY26 Q1 $38.7M
FY26 Q2 $47M
Revenue growth, TTM YoY Editas Medicine, Inc.
-100% 0% 100% 200% 300% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -4.0% Revenue growth, TTM YoY, FY23 Q4: 296.3% Revenue growth, TTM YoY, FY24 Q1: 204.5% Revenue growth, TTM YoY, FY24 Q2: 247.0% Revenue growth, TTM YoY, FY24 Q3: 150.9% Revenue growth, TTM YoY, FY24 Q4: -58.6% Revenue growth, TTM YoY, FY25 Q1: -48.4% Revenue growth, TTM YoY, FY25 Q2: -42.0% Revenue growth, TTM YoY, FY25 Q3: -24.9% Revenue growth, TTM YoY, FY25 Q4: 25.4% Revenue growth, TTM YoY, FY26 Q1: 8.0% Revenue growth, TTM YoY, FY26 Q2: 20.8% 20.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -4.0%
FY23 Q4 296.3%
FY24 Q1 204.5%
FY24 Q2 247.0%
FY24 Q3 150.9%
FY24 Q4 -58.6%
FY25 Q1 -48.4%
FY25 Q2 -42.0%
FY25 Q3 -24.9%
FY25 Q4 25.4%
FY26 Q1 8.0%
FY26 Q2 20.8%
Operating margin (TTM) Editas Medicine, Inc.
-1000% -500% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -847.9% Operating margin (TTM), FY23 Q4: -216.6% Operating margin (TTM), FY24 Q1: -266.8% Operating margin (TTM), FY24 Q2: -317.8% Operating margin (TTM), FY24 Q3: -370.0% Operating margin (TTM), FY24 Q4: -777.3% Operating margin (TTM), FY25 Q1: -726.4% Operating margin (TTM), FY25 Q2: -616.9% Operating margin (TTM), FY25 Q3: -428.7% Operating margin (TTM), FY25 Q4: -394.9% Operating margin (TTM), FY26 Q1: -281.3% Operating margin (TTM), FY26 Q2: -161.4% -161.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -847.9%
FY23 Q4 -216.6%
FY24 Q1 -266.8%
FY24 Q2 -317.8%
FY24 Q3 -370.0%
FY24 Q4 -777.3%
FY25 Q1 -726.4%
FY25 Q2 -616.9%
FY25 Q3 -428.7%
FY25 Q4 -394.9%
FY26 Q1 -281.3%
FY26 Q2 -161.4%
FCF margin (TTM) Editas Medicine, Inc.
-800% -600% -400% -200% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -634.9% FCF margin (TTM), FY23 Q4: -175.2% FCF margin (TTM), FY24 Q1: -217.6% FCF margin (TTM), FY24 Q2: -255.9% FCF margin (TTM), FY24 Q3: -309.8% FCF margin (TTM), FY24 Q4: -678.1% FCF margin (TTM), FY25 Q1: -600.7% FCF margin (TTM), FY25 Q2: -526.8% FCF margin (TTM), FY25 Q3: -389.6% FCF margin (TTM), FY25 Q4: -409.3% FCF margin (TTM), FY26 Q1: -364.6% FCF margin (TTM), FY26 Q2: -256.5% -256.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -634.9%
FY23 Q4 -175.2%
FY24 Q1 -217.6%
FY24 Q2 -255.9%
FY24 Q3 -309.8%
FY24 Q4 -678.1%
FY25 Q1 -600.7%
FY25 Q2 -526.8%
FY25 Q3 -389.6%
FY25 Q4 -409.3%
FY26 Q1 -364.6%
FY26 Q2 -256.5%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 6 14 32 21 91 26 20 78 32 41 47
EBITDA −96 −117 −110 −138 −131 −188 −220 −163 −245 −155 −73
Operating income −97 −120 −114 −141 −135 −193 −226 −169 −251 −160 −76
Net income −97 −120 −110 −134 −116 −193 −220 −153 −237 −160 −74
Diluted EPS −$3.02 −$2.98 −$2.33 −$2.68 −$1.98 −$2.85 −$3.21 −$2.02 −$2.88 −$1.80 −$0.73
Growth (year on year)
Revenue — +126.8% +132.6% −35.7% +341.9% −71.8% −22.8% +296.3% −58.6% +25.4% +20.8%
Margins
EBITDA margin <−999% −854.1% −345.9% −672.6% −144.3% −736.3% <−999% −208.8% −759.2% −381.9% −156.2%
Operating margin <−999% −873.6% −356.1% −686.4% −148.6% −756.1% <−999% −216.6% −777.2% −394.9% −161.4%
Net margin <−999% −876.5% −344.3% −651.4% −127.8% −753.6% <−999% −196.1% −733.7% −395.0% −157.3%
Free-cash-flow margin −887.8% −83.6% −158.0% −228.1% −206.1% −672.5% −920.6% −175.2% −678.1% −409.3% −256.5%
Cash flow
Cash from operations −50 −9 −46 −41 −180 −164 −177 −132 −210 −165 −120
Capital spending 3 2 5 6 7 8 4 5 9 1 1
Free cash flow −54 −11 −50 −47 −187 −172 −181 −137 −219 −166 −121
Stock-based pay 17 23 27 27 23 43 29 20 21 10 9
Free cash flow after stock pay −71 −35 −77 −74 −210 −215 −211 −157 −241 −176 −129
Balance sheet
Cash 185 147 135 238 140 204 142 124 132 147 182
Total debt 0 0 0 0 0 0 0 0 57 59 56
Net debt (negative = net cash) −185 −147 −135 −238 −140 −204 −142 −124 −74 −88 −126
Diluted shares 32m 40m 47m 50m 59m 68m 69m 76m 82m 89m 101m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $237m
Short-term assets $218mLonger-term assets $19m
What it owes, and who funded it · $237m
Short-term liabilities $68mLonger-term liabilities $64mShareholders' equity $105m
  • Short-term assets cover short-term liabilities $218m of assets due within a year against $68m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $218m short-term assets against $64m of longer-dated liabilities.
  • More cash than debt $182m of cash against $56m of debt.
  • Debt below 40% of shareholders' equity Debt is 53% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$120m of operating cash flow against $56m of debt.
  • Operating profit covers interest at least five times over Operating income of −$76m against $4m of interest.

From Editas Medicine, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+21.7%
year over year
R&D spending
180.7%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated EDIT SPRO STRO OCUL LXRX GOSS Median
Revenue, last 12 months $47m $47m $46m $52m $41m $53m $56m
Revenue growth, last 12 months 20.8% −3.3% −56.3% −8.1% −29.0% 32.4% 12.6%
Revenue growth, 3-year average 34.5% −4.7% −7.0% −1.6% 366.7% — 13.7%
Revenue growth, latest quarter 232.3% −100.0% −84.6% 0.1% −97.6% −19.6% 10.2%
Gross margin — — — 87.1% 99.1% — 82.9%
Operating margin −161.4% 12.8% −319.6% −603.0% −131.4% −311.7% −189.4%
Operating margin, 3-year average −365.3% −30.8% −192.8% −397.7% <−999% −252.1% −363.5%
Net margin −157.3% 15.7% −395.2% −579.1% −147.4% −235.0% −169.8%
Cash from operations / revenue −255.0% 41.7% −317.7% −457.7% −156.7% −305.2% −168.0%
Free-cash-flow margin −256.5% 41.7% −330.9% −490.1% −156.7% −305.2% −162.4%
Free-cash-flow margin, 3-year average −346.4% −12.3% −208.2% −318.3% <−999% −231.0% −310.0%
Stock pay / revenue 18.4% 8.5% 14.8% 102.4% 30.4% 26.9% 20.0%
Change in share count 21.7% 9.1% 20.6% 26.4% 7.9% 14.3% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 20.8% 12.6% 77 of 172
Change in growth rate Growth +12.9pp -0.1pp 41 of 172
Operating margin Profitability -161.4% -189.4% 85 of 175
Net margin Profitability -157.3% -157.3% 90 of 180
Free-cash-flow margin Cash generation -256.5% -145.4% 109 of 176
Stock pay as % of revenue Cash generation 18.4% 19.2% 88 of 179
Long-term debt as % of assets Balance sheet 20.3% 20.6% 39 of 78
Change in share count Balance sheet 21.7% 7.9% 116 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$390M
Institutions reporting
213
Shares held vs prior quarter
▲ 132.1%
Positions opened / closed
35 / 24

Top buyers and sellers, Q2 2026: 110 institutions bought and 65 sold ; the biggest buyer was Tcg Crossover Management, LLC (+11.1M shares) and the biggest seller Renaissance Technologies LLC (−1.5M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Tcg Crossover Management, LLC $36M 11.1M 9.2% New
Blackrock, Inc. $34.3M 10.6M 8.8% ▲ 14.3%
ADAR1 Capital Management, LLC $28.8M 8.9M 7.4% New
RA Capital Management, L.P. $28.8M 8.9M 7.4% New
Commodore Capital LP $28.8M 8.9M 7.4% New
Vanguard Capital Management LLC $19.9M 6.1M 5.1% ▲ 46.1%
Paradigm Biocapital Advisors LP $18.1M 5.6M 4.6% New
Opaleye Management Inc. $12.5M 3.9M 3.2% ▲ 100.4%
Vanguard Portfolio Management LLC $11.7M 3.6M 3.0% ▲ 14.3%
Woodline Partners LP $11.5M 3.6M 3.0% New
Vivo Capital, LLC $11.5M 3.6M 3.0% New
Gordonmd Global Investments LP $10.1M 3.1M 2.6% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Editas Medicine, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $106,706 14 trades by 3 insiders · 100% under pre-set plans
Net ▼ $106,706 net selling
Insider Date Trade Shares Price Value
O'Neill Gilmore Neil CEO September 3, 2026 Sell pre-set plan 5,124 $3.04 $15,577
Parison Amy SVP, Chief Financial Officer September 3, 2026 Sell pre-set plan 453 $3.04 $1,377
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER September 3, 2026 Sell pre-set plan 709 $3.04 $2,155
Parison Amy SVP, Chief Financial Officer August 3, 2026 Sell pre-set plan 678 $2.58 $1,749
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER July 28, 2026 Sell pre-set plan 4,928 $2.67 $13,158
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER June 3, 2026 Sell pre-set plan 731 $2.70 $1,974
O'Neill Gilmore Neil CEO June 3, 2026 Sell pre-set plan 15,380 $2.70 $41,526
Parison Amy SVP, Chief Financial Officer June 3, 2026 Sell pre-set plan 464 $2.70 $1,253
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER March 3, 2026 Sell pre-set plan 749 $2.02 $1,513
Parison Amy SVP, Chief Financial Officer March 3, 2026 Sell pre-set plan 474 $2.02 $957
O'Neill Gilmore Neil CEO March 3, 2026 Sell pre-set plan 5,394 $2.02 $10,896
Parison Amy SVP, Chief Financial Officer December 3, 2025 Sell pre-set plan 461 $2.15 $991

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 14 trades and filings

No trades in Editas Medicine, Inc. disclosed in the last 12 months; 14 earlier trades on record.

  • Daniel S. Goldman(D-NY 10):Sale (full), $1,001 - $15,000, traded April 10, 2023, filed May 19, 2023
  • Donald S. Beyer, Jr.(D-VA 8):Sale (full), $1,001 - $15,000, traded April 14, 2021, filed May 1, 2021
  • Donald S. Beyer, Jr.(D-VA 8):Sale (full), $1,001 - $15,000, traded March 2, 2021, filed April 1, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 5, 2026
  • March 9, 2026
  • November 10, 2025
  • August 12, 2025
  • May 12, 2025

Recent SEC filings

Data status

When each part of this page on Editas Medicine, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Editas Medicine, Inc. in brief

What does Editas Medicine, Inc. do?
Editas Medicine, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Editas Medicine, Inc.'s stock ticker?
Editas Medicine, Inc. trades under the ticker EDIT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Editas Medicine, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Editas Medicine, Inc. reported revenue of $47M, 20.8% higher than a year earlier, according to its SEC filings.
What is Editas Medicine, Inc.'s free cash flow?
Editas Medicine, Inc.'s free-cash-flow margin is -256.5% of revenue over the trailing twelve months, ranking 109 of the 176 biotechnology companies we cover.
Who are Editas Medicine, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Tcg Crossover Management, LLC, Blackrock, Inc. and ADAR1 Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Editas Medicine, Inc.'s market cap?
On November 2, 2026, Editas Medicine, Inc.'s market capitalisation was about $260M and net debt of -$126M. Market figures come from third-party market data and may be delayed.
How much debt does Editas Medicine, Inc. have?
Editas Medicine, Inc.'s debt-to-equity ratio is 52.9%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Editas Medicine, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Editas Medicine, Inc. are Spero Therapeutics, Inc., Sutro Biopharma, Inc., Ocular Therapeutix, Inc, Lexicon Pharmaceuticals, Inc. and Gossamer Bio, Inc. The side-by-side comparison below sets their revenue, margins and growth against Editas Medicine, Inc.'s.
Are insiders buying or selling Editas Medicine, Inc. stock?
Over the last 12 months, Editas Medicine, Inc.'s directors and officers reported 0 open-market purchases and 14 sales on Form 4. The insider trading page charts every trade.
When is Editas Medicine, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Editas Medicine, Inc. announces its own schedule.